Sökresultat med upphovsmän

1

Chronic Lung Disease after Premature Birth av Vivek Subbiah

Publicerad 2008

Hämta fulltext
Carta

Lägg till i favoriter

Sparad:
2

The next generation of evidence-based medicine av Vivek Subbiah

Publicerad 2023

Hämta fulltext Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
3

Tissue-agnostic cancer therapies: promise, reality, and the path forward av Vivek Subbiah

Publicerad 2025

Hämta fulltext
Artigo

Lägg till i favoriter

Sparad:
4

Challenging Standard-of-Care Paradigms in the Precision Oncology Era av Vivek Subbiah, Razelle Kurzrock

Publicerad 2018

Hämta fulltext Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
5

Managing Cancer Care during the COVID-19 Pandemic and Beyond av Omar Alhalabi, Vivek Subbiah

Publicerad 2020

Hämta fulltext Hämta fulltext
Artigo

Lägg till i favoriter

Sparad:
6

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis av Vivek Subbiah, Razelle Kurzrock

Publicerad 2023

Hämta fulltext
Artigo

Lägg till i favoriter

Sparad:
7

Tumor-agnostic drug development in dMMR/MSI-H solid tumors av Deepak Bhamidipati, Vivek Subbiah

Publicerad 2023

Hämta fulltext Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
8

Clinical development and management of adverse events associated with FGFR inhibitors av Vivek Subbiah, Srđan Verstovšek

Publicerad 2023

Hämta fulltext Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
9

Advances in Targeting RET-Dependent Cancers av Vivek Subbiah, Gilbert J. Cote

Publicerad 2020

Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
10

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy av Mohamed A. Gouda, Vivek Subbiah

Publicerad 2023

Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
11

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors av Mohamed A. Gouda, Vivek Subbiah

Publicerad 2023

Hämta fulltext Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
12

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers av Mohamed A. Gouda, Vivek Subbiah

Publicerad 2023

Hämta fulltext Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
13

Clinical Development of BRAF plus MEK Inhibitor Combinations av Vivek Subbiah, Christina S. Baik, John M. Kirkwood

Publicerad 2020

Hämta fulltext Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
14

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm av Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Publicerad 2020

Hämta fulltext Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
15

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives av Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

Publicerad 2017

Hämta fulltext Hämta fulltext
Artigo

Lägg till i favoriter

Sparad:
16

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians av Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

Publicerad 2020

Hämta fulltext
Editorial

Lägg till i favoriter

Sparad:
17

State-of-the-Art Strategies for Targeting RET-Dependent Cancers av Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

Publicerad 2020

Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
18

The abscopal effect in patients with cancer receiving immunotherapy av Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

Publicerad 2023

Hämta fulltext Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
19

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? av Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

Publicerad 2025

Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:
20

The emerging role of PI3K inhibitors for solid tumour treatment and beyond av Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Publicerad 2023

Hämta fulltext
Revisão

Lägg till i favoriter

Sparad:

Chronic Lung Disease after Premature Birth av Vivek Subbiah

The next generation of evidence-based medicine av Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward av Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era av Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond av Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> av Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors av Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors av Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers av Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy av Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors av Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers av Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations av Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm av Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives av Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians av Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers av Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy av Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? av Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond av Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Sökresultat - Vivek Subbiah

Chronic Lung Disease after Premature Birth av Vivek Subbiah

The next generation of evidence-based medicine av Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward av Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era av Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond av Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> av Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors av Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors av Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers av Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy av Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors av Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers av Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations av Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm av Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives av Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians av Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers av Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy av Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? av Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond av Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Sökverktyg:

Relaterade ämnen